CD4 and neoplasm: CAELYX® alone also increased the number of CD3+ T cells in the tumor compared to controls (Fig. 5c), while lowering the number of CD4+ T cells in the tumor microenvironment compared to controls, monotherapies, and the combination therapy (Fig. 5d).